Epilepsy

Clonazepam add‐on therapy for refractory epilepsy in adults and children

Abstract Background Epilepsy affects about 50 million people worldwide, nearly a quarter of whom have drug‐refractory epilepsy. People with drug‐refractory epilepsy have increased risks of premature death, injuries, psychosocial dysfunction, and a reduced quality of life. Objectives To assess the efficacy and tolerability of clonazepam when used as an add‐on therapy foradults and children with […]

Share

Rufinamide add-on therapy for refractory epilepsy

Abstract Background Epilepsy is a central nervous system disorder (neurological disorder). Epileptic seizures are the result of excessive and abnormal cortical nerve cell electrical activity in the brain. Despite the development of more than 10 new antiepileptic drugs (AEDs) since the early 2000s, approximately a third of people with epilepsy remain resistant to pharmacotherapy, often […]

Share

Care delivery and self-management strategies for children with epilepsy

Abstract Background In response to criticism that epilepsy care for children has little impact, healthcare professionals and administrators have developed various service models and strategies to address perceived inadequacies. Objectives To assess the effects of any specialised or dedicated intervention for epilepsy versus usual care in children with epilepsy and in their families. Search methods […]

Share

Losigamone add-on therapy for partial epilepsy

Abstract Background Epilepsy is a common neurologic disorder, affecting approximately 50 million people worldwide; nearly a third of these people have epilepsy that is not well controlled by a single antiepileptic drug (AED) and they usually require treatment with a combination of two or more AEDs. In recent years, many newer AEDs have been investigated […]

Share

Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children

Abstract Background Tonic-clonic convulsions and convulsive status epilepticus (currently defined as a tonic-clonic convulsion lasting at least 30 minutes) are medical emergencies and require urgent and appropriate anticonvulsant treatment. International consensus is that an anticonvulsant drug should be administered for any tonic-clonic convulsion that has been continuing for at least five minutes. Benzodiazepines (diazepam, lorazepam, […]

Share

Psychological treatments for people with epilepsy

Abstract Background Given the significant impact epilepsy can have on the health-related quality of life (HRQoL) of individuals with epilepsy and their families, there is great clinical interest in evidence-based psychological treatments, aimed at enhancing psychological well-being in people with epilepsy. A review of the current evidence was needed to assess the effects of psychological […]

Share

Eslicarbazepine acetate add-on for drug-resistant partial epilepsy

Abstract Background This is an updated version of the Cochrane Review published in the Cochrane Library 2011, Issue 12. The majority of people with epilepsy have a good prognosis, but up to 30% of people continue to have seizures despite several regimens of antiepileptic drugs. In this review, we summarized the current evidence regarding eslicarbazepine […]

Share

EEG for children with complex febrile seizures

Abstract Background Febrile seizures can be classified as simple or complex. Complex febrile seizures are associated with fever that lasts longer than 15 minutes, occur more than once within 24 hours, and are confined to one side of the child’s body. It is common in some countries for doctors to recommend an electroencephalograph (EEG) for […]

Share

The role of high-frequency oscillations in epilepsy surgery planning

Abstract Background Epilepsy is a serious brain disorder characterized by recurrent unprovoked seizures. Approximately two-thirds of seizures can be controlled with antiepileptic medications (Kwan 2000). For some of the others, surgery can completely eliminate or significantly reduce the occurrence of disabling seizures. Localization of epileptogenic areas for resective surgery is far from perfect, and new […]

Share

Intravenous immunoglobulins for epilepsy

Abstract Background Epilepsy is a common neurological condition, with an estimated incidence of 50 per 100,000 persons. People with epilepsy may present with various types of immunological abnormalities, such as low serum immunoglobulin A (IgA) levels, lack of the immunoglobulin G (IgG) subclass and identification of certain types of antibodies. Intravenous immunoglobulin (IVIg) treatment may […]

Share
  • The review abstracts published on this site are the property of John Wiley & Sons, Ltd., and of the Cochrane Review Groups that have produced the reviews.
Share
Share